Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites

References

• Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C. (2009). Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 85:485–494.
   PubMed Web of Science ®Google Scholar
• Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A. (2000). 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497–502.
   PubMed Web of Science ®Google Scholar
• Bélanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. (2009). Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37:1793–1796.
   PubMed Web of Science ®Google Scholar
• Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. (2000). Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679–685.
   PubMedGoogle Scholar
• Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. (2005). S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423–433.
   PubMed Web of Science ®Google Scholar
• Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B. (2000). Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.Toxicol Lett 112–113:333–340.
   PubMed Web of Science ®Google Scholar
• Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ. (2008). Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83:595–600.
   PubMed Web of Science ®Google Scholar
• Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ. (2003). Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125–1133.
   PubMed Web of Science ®Google Scholar
• Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547–558.
   PubMed Web of Science ®Google Scholar
• Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. (2010). Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11:1223–1234.
   PubMed Web of Science ®Google Scholar
• Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S. (2007). Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45:1230–1237.
   PubMed Web of Science ®Google Scholar
• Gounden V, van Niekerk C, Snyman T, George JA. (2010). Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7:32.
   PubMed Web of Science ®Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400.
   PubMed Web of Science ®Google Scholar
• Holthe M, Rakvåg TN, Klepstad P, Idle JR, Kaasa S, Krokan HE, Skorpen F. (2003). Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3:17–26.
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. (2009). CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101–2106.
   PubMed Web of Science ®Google Scholar
• Liu HX, He YQ, Hu Y, Liu Y, Zhang JW, Li W, Wang ZT, Yang L. (2008). Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci 870:84–90.
   PubMedGoogle Scholar
• Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71–75.
   PubMed Web of Science ®Google Scholar
• Miners JO, McKinnon RA, Mackenzie PI. (2002). Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181–182:453–456.
   PubMed Web of Science ®Google Scholar
• Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD. (1999). Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319–1333.
   PubMed Web of Science ®Google Scholar
• Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. (2010). Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38:1218–1229.
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300.
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. (2004). Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292:251–265.
   PubMed Web of Science ®Google Scholar